Vapiprost is a small molecule, synthetic thromboxane A2 receptor (TBXA2R) antagonist investigated as an antithrombotic agent for its potential to inhibit platelet aggregation and vasoconstriction in cardiovascular… Read more
Vapiprost is a small molecule, synthetic thromboxane A2 receptor (TBXA2R) antagonist investigated as an antithrombotic agent for its potential to inhibit platelet aggregation and vasoconstriction in cardiovascular conditions such as deep vein thrombosis and occlusive vascular disease. To support rigorous research and development, this category provides high-quality reference standards, including the active pharmaceutical ingredient, its identified impurities, relevant metabolites, and stable isotope-labelled compounds. Pharmaceutical and analytical laboratories utilize these materials for essential quality control processes, including impurity profiling, method validation, and quantitative determination during stability and bioanalytical studies. By serving as reliable benchmarks, these reference standards ensure accuracy, regulatory compliance, and analytical reproducibility when assessing the identity, purity, and potency of Vapiprost-related samples throughout the development lifecycle.